Trials / Unknown
UnknownNCT01861197
Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy of Dovitinib for Squamous NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dovitinib | Dovitinib 500mg daily for 5 days on/ 2 day off until progression |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2015-01-01
- First posted
- 2013-05-23
- Last updated
- 2013-05-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01861197. Inclusion in this directory is not an endorsement.